Top-Rated StocksTop-RatedNASDAQ:JAZZ Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis → The last Republican president? (From The Freeport Society) (Ad) Free JAZZ Stock Alerts $112.91 +0.21 (+0.19%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$111.43▼$113.1050-Day Range$103.94▼$116.4252-Week Range$103.01▼$146.70Volume641,875 shsAverage Volume680,556 shsMarket Capitalization$7.12 billionP/E Ratio23.28Dividend YieldN/APrice Target$190.92 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Jazz Pharmaceuticals alerts: Email Address Jazz Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside69.1% Upside$190.92 Price TargetShort InterestBearish5.41% of Shares Sold ShortDividend StrengthN/ASustainability-1.96Upright™ Environmental ScoreNews Sentiment1.12Based on 11 Articles This WeekInsider TradingSelling Shares$565,989 Sold Last QuarterProj. Earnings Growth18.37%From $15.35 to $18.17 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.92 out of 5 starsMedical Sector17th out of 917 stocksPharmaceutical Preparations Industry4th out of 431 stocks 4.4 Analyst's Opinion Consensus RatingJazz Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 12 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageJazz Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Jazz Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.41% of the outstanding shares of Jazz Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverJazz Pharmaceuticals has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Jazz Pharmaceuticals has recently increased by 3.96%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldJazz Pharmaceuticals does not currently pay a dividend.Dividend GrowthJazz Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreJazz Pharmaceuticals has received a 54.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Leukemia medication", "Lung cancer medication", and "Anticoagulant medication (B01)" products. See details.Environmental SustainabilityThe Environmental Impact score for Jazz Pharmaceuticals is -1.96. Previous Next 4.0 News and Social Media Coverage News SentimentJazz Pharmaceuticals has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Jazz Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest21 people have searched for JAZZ on MarketBeat in the last 30 days. This is an increase of 24% compared to the previous 30 days.MarketBeat Follows13 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 550% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $565,989.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Jazz Pharmaceuticals is held by insiders.Percentage Held by Institutions89.14% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Jazz Pharmaceuticals' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Jazz Pharmaceuticals are expected to grow by 18.37% in the coming year, from $15.35 to $18.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jazz Pharmaceuticals is 23.28, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.40.Price to Earnings Ratio vs. SectorThe P/E ratio of Jazz Pharmaceuticals is 23.28, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 131.23.Price to Earnings Growth RatioJazz Pharmaceuticals has a PEG Ratio of 1.70. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioJazz Pharmaceuticals has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Jazz Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyMillions of Unsuspecting Americans Could be Wiped Out…America’s Most Shocking Financial Story… Behind closed doors in D.C., there is a dark political and economic plot underway. That’s why if you have any savings in the bank or own any assets you want to protect, you must watch this new documentary before it’s too late.You can stream it for free right here. About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ)Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Read More JAZZ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JAZZ Stock News HeadlinesJune 12 at 6:50 AM | insidertrades.comInsider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CAO Sells 163 Shares of StockJune 14 at 6:13 AM | investorplace.com3 Blue-Chip Stocks to Triple Your Wealth by 2026: June EditionJune 13 at 7:35 AM | americanbankingnews.comPatricia Carr Sells 163 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) StockJune 9, 2024 | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) Trading Up 4.3%June 6, 2024 | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) Receives New Coverage from Analysts at The Goldman Sachs GroupJune 3, 2024 | investorplace.com7 Overlooked Stocks Offering Long-Term Stability From the ShadowsJune 1, 2024 | prnewswire.comJazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024May 30, 2024 | prnewswire.comJazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024May 29, 2024 | prnewswire.comJazz Pharmaceuticals to Participate in Upcoming June Investor ConferencesMay 29, 2024 | prnewswire.comZanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract CancerMay 28, 2024 | finance.yahoo.comNodThera Announces Appointment of Daniel Swisher as Chief Executive OfficerMay 23, 2024 | investorplace.com7 Blue-Chip Stocks to Buy Now: May 2024May 22, 2024 | prnewswire.comJazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee VolunteerismMay 17, 2024 | investorplace.com3 Cheap Blue-Chip Stocks to Buy Now: May 2024May 16, 2024 | uk.finance.yahoo.comGlobal Oral Transmucosal Drugs Market Size To Exceed USD 62.3 Billion By 2033 | CAGR Of 6.5%May 10, 2024 | msn.comAvadel Pharma gains during hearing over dispute on FDA approval of a sleep disorder drugMay 9, 2024 | investorplace.com7 Cannabis Stocks to Buy for a Smoking-Hot 2024May 8, 2024 | benzinga.comNeena M Patil Implements A Sell Strategy: Offloads $548K In Jazz Pharmaceuticals StockMay 7, 2024 | finance.yahoo.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) Q1 2024 Earnings Call TranscriptMay 3, 2024 | finance.yahoo.comJazz Pharmaceuticals First Quarter 2024 Earnings: Misses ExpectationsMay 2, 2024 | markets.businessinsider.comBuy Rating Affirmed: Jazz Pharmaceuticals’ Resilient Base and Promising Pipeline Drive Positive OutlookMay 2, 2024 | markets.businessinsider.comOptimistic Outlook for Jazz Pharmaceuticals Despite Q1 ChallengesMay 2, 2024 | markets.businessinsider.comDemystifying Jazz Pharmaceuticals: Insights From 15 Analyst ReviewsMay 1, 2024 | investorplace.comJAZZ Stock Earnings: Jazz Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024May 1, 2024 | sfgate.comJazz: Q1 Earnings SnapshotSee More Headlines Receive JAZZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today6/14/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:JAZZ CUSIPG5087110 CIK1232524 Webwww.jazzpharma.com Phone(531) 634-7800Fax353-1634-7850Employees2,800Year Founded2003Price Target and Rating Average Stock Price Target$190.92 High Stock Price Target$230.00 Low Stock Price Target$131.00 Potential Upside/Downside+69.1%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)$4.85 Trailing P/E Ratio23.28 Forward P/E Ratio7.36 P/E Growth1.7Net Income$414.83 million Net Margins8.61% Pretax Margin6.28% Return on Equity27.86% Return on Assets8.91% Debt Debt-to-Equity Ratio1.38 Current Ratio2.27 Quick Ratio1.90 Sales & Book Value Annual Sales$3.83 billion Price / Sales1.86 Cash Flow$28.30 per share Price / Cash Flow3.99 Book Value$59.36 per share Price / Book1.90Miscellaneous Outstanding Shares63,040,000Free Float60,266,000Market Cap$7.12 billion OptionableOptionable Beta0.62 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Bruce C. Cozadd (Age 60)Co-Founder, Chairman & CEO Comp: $2.44MMs. Heidi Manna (Age 52)Executive VP & Chief People Officer Dr. Jed Black M.D.Senior Vice President of Sleep & CNS MedicineMs. Samantha Pearce (Age 58)Senior Vice President of Europe & International Mr. John MillerSenior Vice President of Corporate StrategyMs. Aislinn DoodyCompany SecretaryDr. Katherine A. LittrellVice President of Investor RelationsMr. Joshua R. Steinerman M.D.Vice President of NeuropsychiatryMore ExecutivesKey CompetitorsMirati TherapeuticsNASDAQ:MRTXUltragenyx PharmaceuticalNASDAQ:RAREArrowhead PharmaceuticalsNASDAQ:ARWRACADIA PharmaceuticalsNASDAQ:ACADBausch Health CompaniesNYSE:BHCView All CompetitorsInsiders & InstitutionsPatricia CarrSold 163 sharesTotal: $17,739.29 ($108.83/share)DekaBank Deutsche GirozentraleBought 23,768 shares on 6/4/2024Ownership: 0.183%Teachers Retirement System of The State of KentuckyBought 50,300 shares on 5/28/2024Ownership: 0.256%Boston PartnersSold 2,875 shares on 5/28/2024Ownership: 0.015%Burney Co.Sold 19,687 shares on 5/22/2024Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions JAZZ Stock Analysis - Frequently Asked Questions Should I buy or sell Jazz Pharmaceuticals stock right now? 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" JAZZ shares. View JAZZ analyst ratings or view top-rated stocks. What is Jazz Pharmaceuticals' stock price target for 2024? 14 equities research analysts have issued 1 year price objectives for Jazz Pharmaceuticals' stock. Their JAZZ share price targets range from $131.00 to $230.00. On average, they anticipate the company's share price to reach $190.92 in the next year. This suggests a possible upside of 69.1% from the stock's current price. View analysts price targets for JAZZ or view top-rated stocks among Wall Street analysts. How have JAZZ shares performed in 2024? Jazz Pharmaceuticals' stock was trading at $123.00 at the beginning of the year. Since then, JAZZ shares have decreased by 8.2% and is now trading at $112.91. View the best growth stocks for 2024 here. When is Jazz Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our JAZZ earnings forecast. How were Jazz Pharmaceuticals' earnings last quarter? Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced its quarterly earnings data on Wednesday, May, 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.53 by $1.55. The specialty pharmaceutical company had revenue of $901.98 million for the quarter, compared to analyst estimates of $938.99 million. Jazz Pharmaceuticals had a net margin of 8.61% and a trailing twelve-month return on equity of 27.86%. What ETFs hold Jazz Pharmaceuticals' stock? ETFs with the largest weight of Jazz Pharmaceuticals (NASDAQ:JAZZ) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Cambria Cannabis ETF (TOKE), Invesco Pharmaceuticals ETF (PJP), First Trust Nasdaq Pharmaceuticals ETF (FTXH), iShares U.S. Pharmaceuticals ETF (IHE), AdvisorShares Pure Cannabis ETF (YOLO) and Strategas Global Policy Opportunities ETF (SAGP). What guidance has Jazz Pharmaceuticals issued on next quarter's earnings? Jazz Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided EPS guidance of 18.150-19.350 for the period, compared to the consensus estimate of 18.930. The company issued revenue guidance of $4.0 billion-$4.2 billion, compared to the consensus revenue estimate of $4.1 billion. What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO? 60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Jazz Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib). Who are Jazz Pharmaceuticals' major shareholders? Jazz Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.23%), LSV Asset Management (3.78%), Polaris Capital Management LLC (2.27%), Capital World Investors (2.27%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (0.76%) and Perpetual Ltd (0.75%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, Jennifer E Cook, Kenneth W O'keefe, Kim Sablich, Mark Douglas Smith, Neena M Patil, Patricia Carr, Patrick G Enright, Peter Gray, Philip L Johnson, Renee D Gala, Rick E Winningham, Robert Iannone and Samantha Pearce. View institutional ownership trends. How do I buy shares of Jazz Pharmaceuticals? Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Jazz Pharmaceuticals have any subsidiaries? The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.Read More This page (NASDAQ:JAZZ) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredThe last Republican president?History shows Donald Trump is poised to go down as the last Republican President for a generation or more. ...The Freeport Society | SponsoredThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technol...Porter & Company | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jazz Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Jazz Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.